Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.
Inappropriate signaling through the epidermal growth factor receptor family (EGFR1/ERBB1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) of receptor tyrosine kinases leads to unregulated activation of multiple downstream signaling pathways that are linked to cancer formation and progression. In particular,...
Main Authors: | Jimson W D'Souza, Smitha Reddy, Lisa E Goldsmith, Irina Shchaveleva, James D Marks, Samuel Litwin, Matthew K Robinson |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4227695?pdf=render |
Similar Items
-
The production of anti-idiotopic antibodies to monoclonal anti-RhD antibodies
by: Evans, Rachael Yvonne
Published: (2001) -
Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect
by: Tao Chen, et al.
Published: (2020-10-01) -
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
by: Stephen R. Adams, et al.
Published: (2016-10-01) -
Anticorpo monoclonal anti-fator VIII Monoclonal antibody anti-factor VIII
by: Eurípides Ferreira
Published: (2006-06-01) -
Monoclonal Anti-Idiotype Antibody to HSV-1 Neutralizing Monoclonal Antibody: Production and Characterization
by: Veenita S. Dar, et al.
Published: (1993-01-01)